Inovio Pharmaceuticals, Inc. (INO) Earnings History
Annual and quarterly earnings data from 1999 to 2025
Loading earnings history...
INO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
INO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | 100.0% | -51616.9% | -49254.3% |
| 2023 | 100.0% | -17300.3% | -16239.9% |
| 2022 | 100.0% | -2607.4% | -2726.7% |
| 2021 | 100.0% | -16972.3% | -17109.9% |
Download Data
Export INO earnings history in CSV or JSON format
Free sign-in required to download data
Inovio Pharmaceuticals, Inc. (INO) Earnings Overview
As of May 8, 2026, Inovio Pharmaceuticals, Inc. (INO) reported trailing twelve-month net income of -$84.95B, reflecting +54.2% year-over-year growth. The company earned $-181.17 per diluted share over the past four quarters.
Looking at the long-term picture, INO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2003.
Inovio Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NVAX (-$88M net income, 39.2% margin), OCGN (-$68M net income, -1537.4% margin), DVAX (-$43M net income, 9.9% margin), INO has comparable earnings metrics. Compare INO vs NVAX →
INO Earnings vs Peers
Earnings metrics vs comparable public companies
INO Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$84.95B | -79100.6% | -$86.82B | $-1.81 | - | - |
| 2024 | -$107M | +20.6% | -$112M | $-3.95 | -49254.3% | -51616.9% |
| 2023 | -$135M | +51.7% | -$144M | $-6.09 | -16239.9% | -17300.3% |
| 2022 | -$280M | +7.9% | -$268M | $-14.07 | -2726.7% | -2607.4% |
| 2021 | -$304M | -82.5% | -$301M | $-1.42 | -17109.9% | -16972.3% |
| 2020 | -$166M | -39.4% | -$124M | $-1.07 | -2245.4% | -1674.2% |
| 2019 | -$119M | -23.1% | -$111M | $-0.97 | -2902.8% | -2702.1% |
| 2018 | -$97M | -9.9% | -$94M | $-1.05 | -318.1% | -308.7% |
| 2017 | -$88M | -19.6% | -$84M | $-1.08 | -208.9% | -198.1% |
| 2016 | -$74M | -152.6% | -$76M | $-1.01 | -208.5% | -215.5% |
See INO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonINO — Frequently Asked Questions
Quick answers to the most common questions about buying INO stock.
Is INO growing earnings?
INO EPS is $-181.17, with earnings growth accelerating to +54.2%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-84.9B.
What are INO's profit margins?
Inovio Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are INO's earnings?
INO earnings data spans 1999-2025. The accelerating earnings trend is +54.2% YoY. Historical data enables comparison across business cycles.